Inhibitor Therapeutics, Inc.
itraconazole
Basal Cell Carcinoma Nevus Syndrome (BCCNS)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on itraconazole for Basal Cell Carcinoma Nevus Syndrome (BCCNS) is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Based on the Company’s current development plan, Inhibitor believes this PK study is expected to represent the final clinical study required prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for it”